Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare moversSeekingAlpha.com: All News • about 2 months ago
Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...
Share to Feed
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...
Gagnants
Le titre Ainos (NASDAQ:AIMD) a grimp jeudi de 101,78% 2,26 dollars lors de la session after-market.
Le titre Immuron (NASDAQ:IMRN) a grimp de 36,26% 6,20 dollars.
L'action Talis...
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Highlights: Travelan sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan YTD Jan 2024 sales $2.1 millionUSA Travelan YTD Jan 2024 sales $0.6...
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Highlights: Record half yearly Travelan sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales...